39235-63-7

Upstream product

• 110-71-4 1,2-dimethoxyethane 
• 120-57-0 piperonal 
• 124-41-4 sodium methylate 
• 7757-83-7 sodium sulfite 
• 63860-91-3 1-(3,4-methylenedioxyphenyl)-1-chloro-2-methyl-2-nitropropane 
• 54508-53-1 2,2-dimethyl-3-<3,4-(methylenedioxy)phenyl>propionic acid 
• 20850-43-5 5-(chloromethyl)-1,3-benzodioxole 
• 81279-27-8 1--1,1-dimethyl-2-<3,4-(methylenedioxy)phenyl>ethane 

Relevant academic research and scientific papers

New bronchospasmolytic compounds and process for their preparation

New bronchospasmolytic compounds of the formula (X) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are the same or different and are each H, OH, OCH3, OC2H5, halogen; or R1 and R2 together form the chain -O-CH2-O- or -O-CF2-O-;, R3 is H or CH3;, R5 is H or -CO-R7;, R6 is H, OH, OCH3, OC2H5 or halogen;, R7 is a straight or branched alkyl grup with 1-16 carbon atoms, aryl, -NHCH3 or -N(CH3)2, as well as their use and a process for their preparation.

Effects of Certain Hallucinogenic Amphetamine Analogues on the Release of Serotonin from Rat Brain Synaptosomes

The enantiomers of 3,4-(methylenedioxy)amphetamine (MDA), p-methoxyamphetamine (PMA), and N-Me-MDA (MDMA), along with their α,α-dimethylated derivatives, were evaluated for an effect on the release of serotonin from rat whole brain synaptosomes.The amphetamine isomers were all potent in inducing the release of serotonin at bath concentrations of 1 and 10 μM but were inactive at 0.1 μM.No significant difference in isomer potency was observed at the 10-μM concentration.However, at 1 μM the (+) isomer of MDMA was more effective in inducing release than was the (-) isomer.Since it is the (+) isomer which is clinically active, this result suggests that transmitter release may play a role in the biological activity of MDMA.By contrast, the α,α-dimethyl compounds were not effective in releasing serotonin, even at the highest bath concentration.

Novel benzylalcohol derivative and process for preparing the same

A benzylalcohol derivative of the formula: STR1 wherein R is hydroxy, benzyloxy, alkoxy of one to 4 carbon atoms or halogen, and Ring A is monomethoxyphenyl, dimethoxyphenyl, trimethoxyphenyl or 3,4-methylenedioxyphenyl is prepared by reducing a compound of the formula: STR2 wherein R' is benzyloxy, alkoxy of one to 4 carbon atoms or halogen, and Ring A is the same as defined above, and when R' is benzyloxy, if required, further subjecting the product to catalytic hydrogenation. The compounds (I) and pharmaceutically acceptable acid addition salts thereof are used as anti-diabetic agents.

Preparation of ethylamine derivatives

A process for preparing a compound of the formula STR1 wherein R and R1 independently are selected from hydrogen and C1 -C4 alkyl groups, which comprises catalytically hydrogenating a compound of formula STR2 wherein R and R1 are as defined above and X is halogen using platinum oxide as catalyst.